Finally got a chance to watch this and it’s pretty impressive. My take:
- Approval has a very high probability of happening at or possibly even before September
- The team is ramping up substantially for marketing, sales and distribution and has an indication from insurers that around $700 per month (and per unit) is viable - possibly more
- Sales of SB for Kaken in Japan in year 2 have been 300,000 units annually
- Pure speculation of course but if we were to achieve that 300,000 annually in the US, times $700, that would be $210m revenue. Say the margin is around 50% of revenue, that’s profitability of $105m. Take a conservative PE of 15, that’s a market cap of around $1.6B.
- Considering the US market is three times the size - well you get the picture.
- Meanwhile, big pharma has been approaching them regularly.
Looking good!
Finally got a chance to watch this and it’s pretty impressive....
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $678.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.0¢ | 36.5¢ | $890.2K | 2.388M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 174511 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 375004 | 6 |
View Market Depth
| Last trade - 14.32pm 15/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |